Welcome to our dedicated page for RemSleep Holdings SEC filings (Ticker: RMSL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on RemSleep Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into RemSleep Holdings's regulatory disclosures and financial reporting.
RemSleep Holdings, Inc. (RMSL) reports that Fruci & Associates II, PLLC resigned as its independent registered public accounting firm effective July 17, 2026. The company states the resignation was amicable and not due to any disagreements over accounting principles, disclosures, or auditing scope or procedures.
RemSleep is in the process of engaging a successor PCAOB-registered firm and plans to announce the appointment and provide additional required disclosures once the engagement is formalized. Current management, which took over during a second-quarter 2026 change in control and leadership transition, is reviewing accounting records and internal financial controls.
In connection with this transition, management has identified issues relating to the recognition, classification, and timing of certain liabilities, indebtedness, and payments affecting second-quarter 2026 information. An additional review of the quarter ended June 30, 2026 will be conducted, which may result in adjustments and could lead to amendments or a restatement if determined appropriate.
REMSleep Holdings, Inc. reported no revenue for the six months ended June 30, 2026 and a net loss of $393,410, reflecting ongoing operating and financing costs without offsetting sales. Total assets were $153,863, against total liabilities of $434,791, resulting in negative shareholders’ equity of $(280,928) and an accumulated deficit of $(18,684,466).
Operating activities used $418,377 of cash, which was partially funded by $203,863 of cash from financing activities, including $35,000 in new convertible notes and common stock issuances. The company issued 80,419,997 new common shares, bringing total common shares outstanding to 1,739,610,123 as of June 30, 2026.
Management discloses substantial doubt about the company’s ability to continue as a going concern due to recurring losses, negative cash flows and reliance on external financing. Disclosure controls and procedures were concluded to be not effective because of a lack of segregation of duties.
REMSleep Holdings, Inc. reports first-quarter 2026 results showing no revenue and a larger net loss of $289,924, compared with $85,488 a year earlier. Total assets were $223,512 against liabilities of $346,063, resulting in negative equity of $122,551.
The company had cash of $87,953 and used $176,561 of cash in operating activities, funded in part by $50,000 of new convertible debt. An accumulated deficit of $18.58 million and recurring losses led management to state there is substantial doubt about its ability to continue as a going concern.
During the quarter, 35,419,997 common shares were issued on conversion of debt, bringing common shares outstanding to 1,694,610,123 as of June 9, 2026. Subsequent events include a change in control, a new management team, relocation of operations to Florida, and approval of 45,000,000 restricted shares as equity compensation and settlement.
RemSleep Holdings, Inc. reported a change in control, major leadership turnover, large equity compensation grants, and a shift in its operating model. Control of the company moved to 1000152403 ONTARIO INC through private, all-cash purchases of preferred shares from existing holders, alongside assumption of approximately $300,000 of issuer and/or preferred shareholder obligations.
Multiple senior officers, including the prior CEO, COO/Chairman, and President/Treasurer/Secretary, resigned effective May 27, 2026. The Board installed a new team: Teresita Rubio as Treasurer and Chairman, Dr. Sanja Pekovic as CEO, Peter Downey as Interim President, and Irina Veselinovic as Secretary, with tight limits placed on the President’s unilateral authority over share issuance and bank accounts.
The Board approved compensatory issuances of 15,000,000 restricted common shares to Scott Hasselbring and 30,000,000 restricted common shares to Roman Israel Wood in lieu of cash. RemSleep closed its Georgia office, relocated operations and a new warehouse to Florida, and is transitioning from a local “cash and carry” model toward internet-focused e-commerce and e-retail channels. The company re-engaged its auditor to complete a late Q1 filing within the available extension period and updated Nevada corporate records to reflect the governance changes.
RemSleep Holdings, Inc. notified the SEC that it could not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 because it needs additional time for its independent registered public accounting firm to complete its review. The company intends to file the Form 10-Q on or before April 20, 2026.
The notification was signed by Roman I. Wood, Chief Executive Officer, on May 15, 2026. The filing indicates the delay is being made pursuant to Rule 12b-25 and does not state that the company expects a significant change in results for the quarter.
REMSleep Holdings is shifting from selling CPAP machines to commercializing its patented DeltaWave nasal pillow system, but remains deeply loss-making and dependent on external funding. In 2025, revenue fell to $16,721 from $117,185 as the company exited prior CPAP sales.
The net loss widened to $3,020,300, and accumulated deficit reached $18,291,056. Cash was $214,514 at year-end, funded partly by $254,000 of convertible notes, creating a derivative liability of $63,920 and additional dilution. Auditors and management disclose substantial doubt about the company’s ability to continue as a going concern. While DeltaWave gained FDA 510(k) clearance, an expanded indication in January 2026, Medicare reimbursement coding, and a February 2026 commercial launch, execution depends on securing adequate financing. 2025 results also include $2,160,000 of non-cash related-party stock compensation to the former CEO and COO, significantly inflating expenses.
RemSleep Holdings, Inc. notified the SEC that it cannot timely file its Annual Report on Form 10-K for the year ended December 31, 2025 because additional time is required for its independent registered public accounting firm to complete the audit. The company intends to file the Form 10-K by or before April 15, 2026.
REMSleep Holdings reports the passing of founder, Chairman, and CEO Thomas Wood on February 26, 2026, shortly after achieving FDA clearance and commercial readiness for its DeltaWave Nasal Pillow System. His death created vacancies in both the CEO and Board chair roles.
Effective March 2, 2026, Anita Michaels, Mr. Wood’s sister and now majority shareholder through inherited super-voting preferred shares, elected herself Chairman and added Jeffrey Marshall and Alexander Johnson as directors. The reconstituted Board unanimously ratified these actions.
Jeffrey Marshall was also appointed Chief Executive Officer under an Executive Employment Agreement providing a base salary and performance-based stock options of up to 7% of fully diluted capitalization, subject to milestones and standard termination and severance terms. Alexander Johnson joins as a director with prior advisory experience to the Company on capital formation and governance.
REMSleep Holdings (RMSL) reported Q3 2025 results showing a much larger loss while beginning sales of its DeltaWave CPAP interface. Revenue for the quarter was $7,454, down from $37,260 a year earlier, and the quarterly net loss widened to $2,312,146. For the first nine months of 2025, revenue was $12,278 versus $122,735 in 2024, with a net loss of $2,685,406 and an accumulated deficit of $17,956,162.
Results were heavily affected by a $2,160,000 non-cash compensation expense from issuing Series C preferred stock to the CEO and a related party. The company relies on multiple convertible promissory notes from 1800 Diagonal, which generated significant interest expense and share issuances totaling 73,214,713 shares in the period. At September 30, 2025, cash was $343,948 and net cash used in operating activities was $373,395. Management states there is substantial doubt about the company’s ability to continue as a going concern. Common shares outstanding were 1,617,658,094 as of November 18, 2025.
RemSleep Holdings, Inc. filed a Form 12b-25 to notify a late filing of its Quarterly Report on Form 10-Q for the period ended September 30, 2025. The company cites the need for additional time for its independent registered public accounting firm to complete its review.
RemSleep states it intends to file the Form 10-Q by or before November 19, 2025, consistent with the Rule 12b-25 provision that permits a five-calendar-day extension for quarterly reports.